ArticleVirology2022
The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 - Results from a prospective cohort of outpatient COVID-19 cases.
Article in Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.Communications medicine · 2026Article
- SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Fallow deer approaching humans are more likely to be seropositive forRoyal Society open science · 2025Article
- Viral dynamics and factors associated with duration of COVID-19 positivity: evidence from the first-three epidemiological waves in Cameroon.BMC infectious diseases · 2025Article
- Article
- Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).Biomedicines · 2024Review
- SARS-CoV-2 viremia but not respiratory viral load is associated with respiratory complications in patients with severe COVID-19.BMC pulmonary medicine · 2024Article
- Symptom propagation in respiratory pathogens of public health concern: a review of the evidence.Journal of the Royal Society, Interface · 2024Review
- Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection.Open forum infectious diseases · 2023Article
- Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.Virology journal · 2023Article
- Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion.Nature communications · 2023Article
- Impact of Omicron Variant Infection on Assessment of Spike-Specific Immune Responses Using the EUROIMMUN Quan-T-Cell SARS-CoV-2 Assay and Roche Elecsys Anti-SARS-CoV-2-S.Diagnostics (Basel, Switzerland) · 2023Article
- Plasma SARS-CoV-2 RNA elimination and RAGE kinetics distinguish COVID-19 severity.Clinical & translational immunology · 2023Article
- Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk factors for disease progression and severity of SARS-CoV-2 infections require an understanding of acute and long-term virological and immunological dynamics. Fifty-one RT-PCR positive COVID-19 outpatients were recruited between May and December 2020 in Munich, Germany, and followed up at multiple defined timepoints for up to one year. RT-PCR and viral culture were performed and seroresponses measured. Participants were classified applying the WHO clinical progression scale. Short symptom to test time (median 5.0 days; p = 0.0016) and high viral loads (VL; median maximum VL: 3∙10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.